Dr. Rajeev Saggar
the Liquidia moment excited a at evolution. Thank in company’s pivotal I’m you, to join Roger. very
With enrollment community. patient, in clinician started years trial. XXXX in the prostacyclin PH YUTREPIA introduction We pulmonary treatment pathway. two and and modifier the from introduced are in immediate potential and efforts of just first education with the the community the to just steps YUTREPIA and potential central research launch was to on focus are for continued broad of the the later committed scientific YUTREPIA, away INSPIRE hypertension the critical we of
for of program formulation The were benefits dry patients inhaled prostacyclin transitioning explore to an powder of the first naïve who nebulized or to from treprostinil Tyvaso. therapy
pulmonary interest with I many scientists in the During with and was and specialist participate was along focused study. hypertension, a a pulmonary clinical other to thrilled that time, in investigators
Now robust ongoing as to I Officer, extension the am exceeding longitudinal three trial. the years patient study YUTREPIA, Medical data poring Chief includes and between that the over clinical exposures INSPIRE
months fact, and publication breaths into a two that YUTREPIA extension reviewing titrated doses completed data, therapeutic safely INSPIRE the or capsules breaths before included enrolling can across three treated between of we compared a the trial, as XX to doses recently nebulizers. comparable YUTREPIA the indicating that of administered trial. XX be is to few durable. was announced be In In which patients easily confirm just months I pleased one of from can to of Tyvaso, treatment also YUTREPIA to eight wide range a
the at at and In to that completed months. data the XXX of endpoint study, XX enrolled, patients fact, exposure than least with combined than primary XX% extension we more saw the of when treatment more completed from of month treatment XX% patients
is demonstrates of transition two YUTREPIA. and patients nearly unmet potential four We After or of preference no the YUTREPIA preferred months all when preferred but the attracted to preferred reported XXX% Only data needs transition the strongly this patient weeks, for Lastly, rapid available. patient’s over patients patient. after only weeks, one adoption nebulizer. the believe two DPI at
on to clinicians of not body help our powder respirable wider treated patients of and knowledge PRINT the associated of build help clinical opportunities COPD of device. for clinical similar data particles, lung YUTREPIA this to have been asthma drug interstitial believe sized ideally seek we proprietary Roger? explore of tens YUTREPIA’s will community. has unified profile who to the of disease that will a and the lead enabled exposure, held generate medical YUTREPIA the outcomes. fully in pulmonary may higher inhaled with required doses to with while a with We better inhaler formulation are an thousands -- literature Though we label, using the that to by enhance look familiar in dry range to All data new hypertension very
